Clinical Trial Update: Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma [Phase 1]

View source ↗

Summary

This Phase 1 trial investigates whether immune responses to the 23-valent pneumococcal polysaccharide vaccine can predict asthma status and outcomes in late ado…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Pneumococcal polysaccharide vaccine, 23-valent (PPSV23) (PPSV23)

Snippet

Sponsor: Rohit Divekar | Conditions: Asthma | Phase 1 | Status: COMPLETED